BioCryst Pharmaceuticals
A Senior Manager of Translational Modeling at BioCryst leads mechanistic modeling strategies for drug discovery and early development, focusing on biologics and protein therapeutics. The role involves designing, validating, and applying PBPK, PK/PD, and QSP models to inform candidate selection, decision-making, and regulatory submissions. This position requires close collaboration with cross-functional teams including DMPK, toxicology, and clinical pharmacology to drive program success.
Headquarters
Durham, North Carolina, United States
Company Size
501-1000 employees
Founded
1986
BioCryst Pharmaceuticals is a global biotech company with over three decades of experience in drug discovery, development, and commercialization, specializing in rare disease therapeutics. Founded in 1986, the company focuses on hereditary angioedema (HAE) and other rare diseases, delivering first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. BioCryst uses a novel, structure-guided approach blending traditional biology and medicinal chemistry with advanced technologies to develop medicines for underserved patient communities worldwide.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals didn’t post a salary, so this is our estimate from similar listings.
8% below the average for this role
Director, Translational PK/PD, PBPK Modeling
Merck & Co., Inc.
Director, Translational PK/PD, PBPK Modeling
MSD
Associate Director
Novartis
Associate Director
Novartis
Director, Translational PK/PD, PBPK Modeling
Merck & Co., Inc.
Principal Scientist II/Senior Principal Scientist, Modeling & Simulation (Dual Level Posting)
Novartis